The North Chicago-based drugmaker is having second thoughts about its $55 billion deal to combine with British counterpart Shire. AbbVie said late Tuesday its board needs to weigh whether it is still a good idea in light of new U.S. tax regulations aimed at cracking down on corporate inversions. Shire called on AbbVie to stick to the deal, reminding its partner about the hefty $1.64 billion breakup fee.
Continue reading at Newsfeed
